Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes

被引：0
|
作者：
Yuan, Peng
Wang, Jiayu
Ma, Fei
Fan, Ying
Luo, Yang
Cai, Ruigang
Zhang, Pin
Li, Qing
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
[4] Chinese Acad Med, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparison of the cost-effectiveness of six cycles of taxotere, doxorubicin, cyclophosphamide (TAC) versus six cycles of fluorouracil, doxorubicin, cyclophosphamide (FAC) in the adjuvant setting of node positive breast cancer with primary and secondary G-CSF prophylaxis
    Mittmann, N.
    Koo, M.
    Alloul, K.
    Trudeau, M.
    VALUE IN HEALTH, 2008, 11 (03) : A10 - A10
  • [42] NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
    Samuel, Jacobs A.
    Wilson, John W.
    Bandos, Hanna
    Elledge, Richard M.
    Robidoux, Andre
    Fehrenbacher, Louis
    Ward, Patrick J.
    Polikoff, Johnathan
    Brufsky, Adam M.
    Provencher, Louise
    Paterson, Alexander H. G.
    Hamm, John T.
    Carolla, Robert L.
    Baez-Diaz, Luis
    Rastogi, Priya
    Julian, Thomas B.
    Wickerham, D. Lawrence
    Swain, Sandra M.
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    CANCER RESEARCH, 2015, 75
  • [43] Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
    Abdel-Razeq, Hikmat
    Saadeh, Salwa S.
    Abu-Nasser, Mahmoud
    Abdulelah, Hazem
    Marie, Lina
    Salam, Murad
    Ali, Basel Al-Haj
    Ibrahim, Mohammad
    Rimawi, Dalia
    ONCOTARGETS AND THERAPY, 2018, 11 : 2091 - 2096
  • [44] Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
    Martin, Miguel
    Ruiz Simon, Amparo
    Ruiz Borrego, Manuel
    Ribelles, Nuria
    Rodriguez-Lescure, Alvaro
    Munoz-Mateu, Montserrat
    Gonzalez, Sonia
    Margeli Vila, Mireia
    Barnadas, Agusti
    Ramos, Manuel
    Del Barco Berron, Sonia
    Jara, Carlos
    Calvo, Lourdes
    Martinez-Janez, Noelia
    Mendiola Fernandez, Cesar
    Rodriguez, Cesar A.
    Martinez de Duenas, Eduardo
    Andres, Raquel
    Plazaola, Arrate
    de la Haba-Rodriguez, Juan
    Manuel Lopez-Vega, Jose
    Adrover, Encarna
    Isabel Ballesteros, Ana
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    Baena-Canada, Jose M.
    Casas, Maribel
    del Carmen Camara, Mara
    Maria Carrasco, Eva
    Lluch, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3788 - +
  • [45] Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study
    Cognetti, F.
    Bruzzi, P.
    De Placido, S.
    De laurentiis, M.
    Boni, C.
    Aitini, E.
    Durando, A.
    Turletti, A.
    Valle, E.
    Garrone, O.
    Puglisi, F.
    Montemurro, F.
    Barni, S.
    Di Blasio, B.
    Gamucci, T.
    Colantuoni, G.
    Olmeo, N.
    Tondini, C.
    Parisi, A. M.
    Bighin, C.
    Pastorino, S.
    Lambertini, M.
    Del Mastro, L.
    CANCER RESEARCH, 2013, 73
  • [46] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes
    Murialdo, Roberto
    Gallo, Maurizio
    Boy, Davide
    Zoppoli, Gabriele
    Tixi, Lucia
    Gonella, Roberta
    Ballestrero, Alberto
    Patrone, Franco
    TUMORI JOURNAL, 2014, 100 (02): : 128 - 135
  • [47] Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
    Bamias, Aristotle
    Papadimitriou, Christos
    Efstathiou, Eleni
    Rodolakis, Alexandros
    Vlahos, Georgios
    Voulgaris, Zannis
    Bozas, Georgios
    Fountzilas, Georgios
    Aravantinos, Gerassimos
    Razis, Evagelia
    Gika, Dimitra
    Dimopoulos, Meletios A.
    BMC CANCER, 2006, 6 (1)
  • [48] Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group
    Aristotle Bamias
    Christos Papadimitriou
    Eleni Efstathiou
    Alexandros Rodolakis
    Georgios Vlahos
    Zannis Voulgaris
    Georgios Bozas
    Georgios Fountzilas
    Gerassimos Aravantinos
    Evagelia Razis
    Dimitra Gika
    Meletios A Dimopoulos
    BMC Cancer, 6
  • [49] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Aristides Polyzos
    Nikolaos Malamos
    Ioannis Boukovinas
    Adamos Adamou
    Nikolaos Ziras
    Kostas Kalbakis
    Stylianos Kakolyris
    Kostas Syrigos
    Pavlos Papakotoulas
    Charalambos Kouroussis
    Nikolaos Karvounis
    Lambros Vamvakas
    Charalambos Christophyllakis
    Athanasios Athanasiadis
    Ioannis Varthalitis
    Vassilis Georgoulias
    Dimitris Mavroudis
    Breast Cancer Research and Treatment, 2010, 119 : 95 - 104
  • [50] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Polyzos, Aristides
    Malamos, Nikolaos
    Boukovinas, Ioannis
    Adamou, Adamos
    Ziras, Nikolaos
    Kalbakis, Kostas
    Kakolyris, Stylianos
    Syrigos, Kostas
    Papakotoulas, Pavlos
    Kouroussis, Charalambos
    Karvounis, Nikolaos
    Vamvakas, Lambros
    Christophyllakis, Charalambos
    Athanasiadis, Athanasios
    Varthalitis, Ioannis
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 95 - 104
12345